我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

复方参鹿颗粒调节相对低危骨髓增生异常综合征患者TGF-β1介导的Treg/Th17细胞变化的临床研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年01期
页码:
33-37
栏目:
临床研究
出版日期:
2019-10-29

文章信息/Info

Title:
Clinic Observation on Effect of Fufang Shenlu Granule on Treg/Th17 Cells andRelated Transcription Factors of the Patients with Lower RiskMyelodysplastic Syndromes by Regulating TGF-β1
文章编号:
1000-2723(2019)01-0033-05
作者:
陆颖佳陈珮邱仲川赵琳胡晓莹朱小勤瞿玮颖封舟黄中迪
(上海中医药大学附属曙光医院血液科,上海 200021)
Author(s):
LU Yingjia CHEN Pei QIU Zhongchuan ZHAO Lin HU Xiaoying ZHU XiaoqinQU Weiying FENG Zhou HUANG Zhongdi
(Shuguang Hospital Shanghai University of Traditional Chinese Medcine, Shanghai 200021, China)
关键词:
骨髓增生异常综合征 复方参鹿颗粒 TGF-β1 IL-2 IL-6 Treg细胞
Keywords:
myelodysplastic syndromes Fufang Shenlu Granule TGF-β1 IL-2 IL-6 Treg cells
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2019.01.007
文献标识码:
A
摘要:
目的探讨复方参鹿颗粒对相对低危MDS患者治疗前后外周血TGF-β1、IL-2、IL-6、Treg细胞、Th17细胞、相关转录因子及比值的影响。方法将40例相对低危MDS患者随机分成中药组和对照组,中药组予复方参鹿颗粒联合西药治疗,对照组单用西药治疗。2组均6个月为1个疗程,共治疗1个疗程,观察外周血TGF-β1、IL-2、IL-6、Treg细胞、Th17细胞、相关转录因子及比值变化。结果治疗后中药组TGF-β1、IL-2表达上升,IL-6表达下降;TGF-β1、IL-2/IL-6比率均高于对照组,IL-6表达低于对照组,均有明显差异(P<0.05)。Treg细胞表达、Treg/Th17比值均高于对照组,具有统计学意义(P<0.05)。治疗后中药组Foxp3mRNA表达、Foxp3/RoRγt比值检测均高于对照组,有明显差异(P<0.05)。结论复方参鹿颗粒可以改善相对低危MDS患者TGF-β1、IL-6、IL-2/IL-6比率、Treg细胞、Treg/Th17比率。提示复方参鹿颗粒改善相对低危MDS患者的造血功能可能通过调整TGF-β1、IL-2/IL-6来调控Treg/Th17比率,进一步改善T细胞免疫功能有关。
Abstract:
Objective To observe the Effect of Fufang Shenlu Granule on TGF-β1, IL-2, IL-6, Treg cells, Th17 cells and related transcription factors of the patients with lower risk myelodysplastic syndromes. Methods 40 patients with lower-risk MDS were randomly divided into treatment group and controlled group. Treatment group was treated with Fufang Shenlu Granule combined with conventional medicine therapy, while the control group was only treated with conventional medicine therapy. Two groups were treated with one course(one course is 6 months). We examined TGF-β1, IL-2, IL-6, Treg cells, Th17 cells, related transcription factors and related ratio after treatment. Results After treatment, TGF-β1, IL-2/IL-6, Treg cells and Treg/Th17 cells, Foxp3 mRNA and the ratio of peripheral blood Foxp3/RoRγt mRNA of treatment group were higher than those of controlled group(P<0.05). IL-6 was lower than controlled group(P<0.05). Conclusion Fufang Shenlu Granule can abjust Treg cells, the balance of Treg/Th17 cells and Foxp3 mRNA and Foxp3/RoRγt mRNA the patients with lower risk myelodysplastic syndromes by TGF-β1, IL-6, and IL-2/IL-6. The mechanism on the treatment efficiency of Fufang Shenlu Granule is associated with Immune dysregulation.

参考文献/References

[1] 中华医学会血液学分会. 骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J]. 中华血液学杂志,2014,35(11):1042-1048.
[2] KORDASTI S Y, INGRAM W, HAYDEN J, et al. CD4+CD25high Foxp3+regulatory T cells in myelodysplastic syndrome(MDS)[J]. Blood,2007,110(3):847-850.
[3] SHAO L L, ZHANG L, HOU Y, et al. Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome[J]. PLoS ONE,2012,7(12):e51339.
[4] KORDASTI S Y, AFZALI B, LIM Z, et al. IL-17 producing CD4(+) T cells,pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome[J]. Br J Haematol,2009,145(1):64-72.
[5] ZHANG S. The role of transforming growth factor β in T helper 17 differentiation[J]. Immunology,2018,155(1):24-35.
[6] HORWITZ D A, ZHENG S G, Gray J D. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets[J]. J Leukoc Biol,2003,74(4):471-478.
[7] 黄中迪,邱仲川,陈珮,等. 复方参鹿颗粒治疗骨髓增生异常综合征的临床观察[J]. 辽宁中医杂志,2008,35(6):865-866.
[8] 中华人民共和国卫生部. 中药新药临床研究指导原则[M]. 北京:中国医药科技出版社,1995:178.
[9] GARCIA M G, SHAN J, FADERL S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome[J]. Leukemia,2007,22(3):538-543.
[10] OLIVA E N, FINELLI C, SANTINI V, et al. Quality of life and physicians perception in myelodysplastic syndromes[J]. Am J Blood Res,2012,2(2):136-147.
[11] LUCIONI C, FINELLI C, MAZZI S, et al. Costs and quality of life in patients with myelodysplastic syndromes[J]. Am J Blood Res,2013,3(3):246-259.
[12] 黄中迪,邱仲川,陈珮,等. 中医药分期治疗MDS临证新得[J]. 中医文献杂志,2007,25(3):33-35.
[13] KOTSIANIDIS I, BOUCHLIOU I, NAKOU E, et al. Kinetics,function and bone marrow trafficking of CD4+CD25+ FOXP3+ regulatory T cells in myelodysplastic syndromes(MDS)[J]. Leukemia,2009,23(3):510-518.
[14] ZHANG Z, LI X, GUO J, et al. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes[J]. Eur J Haematol,2013,90(5):375-384.
[15] ALFINITO F, SICA M, LUCIANO L, et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes[J]. Br J Haematol,2009,148(1):90-98.
[16] ZHAO Z G, WEN X, YU H P, et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes[J]. Cancer Lett,2012,317(2):136-143.
[17] 古学奎,赵珍品. 骨髓增生异常综合征患者血清IL-2和SIL-2R活性检测[J]. 广东医学,2002,23(4):392-393.
[18] MAILLOUX A W, SUGIMORI C, KOMROKJI R S, et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome[J]. J Immunol,2012,189(6):3198-3208.
[19] KAHN J D, CHAMULEAU M E, WESTERS T M, et al. Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes[J]. Haematologica,2015,100(6):e220-e222.
[20] FOZZA C, LONGU F, CONTINI S, et al. Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+ CD25+ CD127(low)regulatory T cells[J]. Acta Haematologica,2012,128(3):178-182.
[21] BHAGAT T D, ZHOU L, SOKOL L, et al. MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling[J]. Blood,2013,121(15):2875-2881.
[22] BETTELLI E, CARRIER Y, GAO W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature(London),2006,441(7090):235-238.
[23] WANG J, XIAO Z. Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes[J]. Stem Cell Investig,2014(1):16.

备注/Memo

备注/Memo:
收稿日期: 2018 - 12- 18
基金项目: 国家自然科学基金资(81403233);上海市卫生和计划生育委员会中医药科研专项课题(2016LP045)
第一作者简介: 陆颖佳(1986-),女,硕士,主治医师,主要从事中医血液病的临床和科研工作。
△通信作者: 黄中迪,E-mail:doczdh@qq.com
更新日期/Last Update: 2019-10-22